Rosacea: Relative risk versus absolute risk of malignant comorbidities - 01/02/19
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: None. |
|
Disclosure: Dr Feldman has received research, speaking, and/or consulting support from a variety of companies, including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Eli Lilly and Company, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, and UpToDate, as well as from the National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhance patients' adherence to treatment. Dr Fleischer was formerly employed by AbbVie, and he is a consultant for Qurient. Mr Tjahjono, Dr Huang, and Dr Cline have no conflicts of interest to disclose. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?